AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two-drug combination for a hard-to-treat form of lung cancer, potentially opening the way to approval ...
By Raechel Thankam Job and Yadarisa Shabong Aug 17 (Reuters) - AstraZeneca said it is ending a late-stage trial that combined one of its key experimental drugs with chemotherapy to treat a certain ...
Pharmaceutical giant AstraZeneca has suffered a fresh setback after pulling the plug on a late-stage lung cancer drug trial. The FTSE 100 group revealed that its Volrustomig treatment, when combined ...
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), one of the world's largest pharmaceutical companies with a major focus on oncology, ended its Phase III eVOLVE-Lung02 trial after an ...
AstraZeneca stock is trading modestly higher as investors weigh double-digit Q2 2026 revenue and EPS growth against the decision to halt a late-stage lung cancer trial and renewed debate over a ...
AstraZeneca AZN1.42%increase; up pointing triangle said it is ending the Phase 3 trial of volrustomig plus chemotherapy for metastatic non-small-cell lung cancer. The Cambridge-based pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results